SuperworthEyePoint market cap EYPT
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $34.9M
- Highest close in our data
- $1.5B
- Dec 2025
EyePoint is worth $34.9M at the close on Oct 23, 2026, at $0.40 a share.
That is down 96% over the last year and down 89% over five years.
Its highest close in our data was $1.5B in Dec 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $34.9M | $34.9M | $1.5B | −98% |
| 2025 | $1.5B | $316.8M | $1.5B | +208% |
| 2024 | $491.4M | $424.4M | $1.2B | −40% |
| 2023 | $816M | $78.2M | $816M | +584% |
| 2022 | $119.3M | $84.2M | $435.1M | −66% |
| 2021 | $352.2M | $135.5M | $496M | +273% |
| 2020 | $94.4M | $46.3M | $208.7M | −42% |
| 2019 | $162.2M | $136.9M | $270M | −4% |
| 2018 | $168.8M | $47.1M | $266M | +245% |
| 2017 | $48.9M | $42M | $88.4M | −16% |
| 2016 | $58.4M | $58.4M | $135.3M | −59% |
| 2015 | $141.8M | $103.3M | $141.8M | +20% |
| 2014 | $118M | $93.8M | $141M | +11% |
| 2013 | $106.5M | $30.1M | $128.1M | +266% |
| 2012 | $29.1M | $24.1M | $57.4M | +26% |
| 2011 | $23.1M | $23.1M | $42.2M | n/a |
Against its peers
Companies in Healthcare nearest EyePoint's size, closest first, today.
| Company | Market cap |
|---|---|
| EYPTEyePoint | $34.9M |
| NEPHNephros | $38.3M |
| ATNMActinium Pharmaceuticals | $47.8M |
| APTAlpha Pro Tech | $56.7M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $83.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on EyePoint
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.